VEGFA and breast carcinoma: Bevacizumab (Avastin), a monoclonal antibody directly targeting vascular endothelial growth factor-A (VEGF-A), has been widely used in clinical trials for patients with melanoma, HER2-negative breast cancer, and so on [4,5].